Eurand's Raw Material Supplier Submits Response to FDA for DMF-Related Questions On EUR-1008 (ZENTASE(r))


PHILADELPHIA, Dec. 23, 2008 (GLOBE NEWSWIRE) -- Eurand N.V. (Nasdaq:EURX), a specialty pharmaceutical company that develops enhanced pharmaceutical and biopharmaceutical products based on its proprietary drug formulation technologies, today announced that its raw material supplier has filed its response to questions relating to the Drug Master File (DMF) raised by the U.S. Food and Drug Administration (FDA) for EUR-1008 (ZENTASE(r)), an innovative pancreatic enzyme replacement product (PEP). This filing is in addition to the response that Eurand submitted in August 2008 to the FDA's questions relating to the manufacture of EUR-1008 in its June 2008 approvable letter.

"We are pleased that our raw material supplier has completed its response to the FDA's questions on the DMF," said Gearoid Faherty, Chairman and Chief Executive Officer. He noted that the FDA recently held an advisory committee meeting for another PEP and that Eurand's raw material supplier had taken note of the panel's recommendations in preparing its reply to the FDA's questions but that Eurand was unsure what, if any, impact the committee's proposed recommendations for that product might have on review or timing of the review of the NDA for EUR-1008.

Separately, the Company announced that late-stage negotiations are continuing for a European partner for EUR-1008, and it expects to finalize a distribution agreement in early 2009.

About EUR-1008 (ZENTASE(r))

Eurand's lead product candidate, EUR-1008 (ZENTASE(r)), is an innovatively formulated pancreatic enzyme product that is being developed for the treatment of exocrine pancreatic insufficiency, a condition associated with cystic fibrosis, chronic pancreatitis and other diseases. The product was developed in response to the 2006 FDA guidance on pancreatic enzyme products, which outlined the need to reduce the variability in enzyme levels and stability of currently marketed enzyme therapies and regulate them under NDAs. EUR-1008 is a highly stable formulation of a porcine pancreatic extract that includes eight key enzymes and a number of coenzymes and cofactors and is biologically similar to the endogenous human pancreatic secretions necessary for proper human digestion. The Company plans to market EUR-1008 in the U.S. and out-license the product outside the U.S.

About Eurand

Eurand is a specialty pharmaceutical company that develops, manufactures and commercializes enhanced pharmaceutical and biopharmaceutical products based on its proprietary drug formulation technologies. Eurand has had four products approved by the FDA since 2001 and has a pipeline of product candidates in development for itself and its collaboration partners. Its technology platforms include bioavailability enhancement of poorly soluble drugs, custom release profiles, taste-masking orally disintegrating tablet (ODT) formulations, and drug conjugation.

Eurand is a global company with facilities in the U.S. and Europe. For more information, visit Eurand's website at www.eurand.com.

Forward-Looking Statement

This release, and oral statements made with respect to information contained in this release, constitutes forward-looking statements. Such forward-looking statements include those which express plan, anticipation, intent, contingency, goals, targets or future development and/or otherwise are not statements of historical fact including, but not limited to the future and status of our NDA filing for EUR-1008, enrollment and future plans for our clinical trials, progress of and reports of results from clinical studies, clinical development plans and product development activities. The words "potentially", "anticipates", "could", "calls for", "expects", and similar expressions also identify forward-looking statements. These statements are based upon management's current expectations and are subject to risks and uncertainties, known and unknown, which could cause actual results and developments to differ materially from those expressed or implied in such statements. Factors that could affect actual results include risks associated with the possibility that the FDA does not approve our NDA relating to EUR-1008 or continues to delay approval; the outcome of any discussions with the FDA; and unexpected delays or additional requirements in preparation of materials for submission to the FDA as a part of our NDA filing, including those relating to Eurand's raw material supplier. Forward-looking statements contained in this press release are made as of this date, and we undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Actual events could differ materially from those anticipated in the forward-looking statements.


            

Coordonnées